[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 4 sources · 3 days · First seen · Last updated

Corcept Therapeutics stock volatility and insider trading

Overview

Corcept Therapeutics experienced a significant stock surge of approximately 228%, reaching a price of $117.17 by August 18, 2026. This growth was linked to an investment by Donald Trump, FDA support for a New Drug Application regarding relacorilant, and positive clinical trial results presented at the American Society of Clinical Oncology annual meeting.

Following the price increase, SEC filings indicated insider selling activity. On August 18, Corcept Therapeutics Director David Mahoney sold 103,606 shares at an average price of $118.25, a transaction totaling roughly $12.25 million. This sale reduced his total stake in the company by 8.37%.

By August 20, Corcept Therapeutics reported quarterly earnings of $0.36 per share, which exceeded analyst estimates.

Entities

Corcept Therapeutics · OppFi Inc. · Food and Drug Administration · Michael Hartung · Fossil Group, Inc.

Timeline

  1. 3 days ago

    [BUSINESS] 2 sources
    Corporate insiders execute various stock transactions

    Various corporate insiders, including executives at Texas Roadhouse and Corcept Therapeutics, have executed significant stock sales and purchases according to recent SEC filings.

  2. 6 days ago

    [BUSINESS] 2 sources
    Corcept Therapeutics stock surges 228% following Trump investment

    Donald Trump’s investment in Corcept Therapeutics has grown approximately 228% since March, driven by FDA developments, positive clinical trial results, and news regarding generic drug tariffs.

Sources

bitcoinethereumnews.com · finbold.com · mommygearest.com · stocknews.com

This summary has been updated 1 time: see revision history